Subtypes


Web

  • http://www.drugs.com/mtm/rituximab.html
  • Rituximab is a cancer medication that interferes with the growth and spread of cancer cells in the body.
  • http://www.medicines.org.uk/emc/medicine/2570
  • Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody representing a glycosylated immunoglobulin with human IgG1 constant regions and murine light-chain and heavy-chain variable region sequences.
  • http://www.aetna.com/cpb/medical/data/300_399/0314.html
  • Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
  • http://www.cancer.gov/about-cancer/treatment/drugs/rituximab/
  • This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
  • http://clltopics.org/RituxanTherapy.htm
  • Harvey's experience coincides with recently published reports on new adverse effects of Rituxan therapy.
  • http://www.lymphomation.org/rituxan.htm
  • Rituxan is the first monoclonal antibody found to be effective and safe for the treatment of cancer in the United States.
  • http://www.diagnosia.com/en/drug/mabthera-100-mg-concentrate-solu...
  • MabThera contains an antibody (rituximab) which is a type of protein.
  • http://www.uwhealth.org/health/topic/multum/rituxan/d04255a1.html
  • Rituximab may cause a serious viral infection of the brain that can lead to disability or death.
  • http://chemocare.com/chemotherapy/drug-info/Rituximab.aspx
  • Rituxan is the trade name for rituximab.In some cases, health care professionals may use the trade name rituxan when referring to the generic drug name rituximab.
  • http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Tre...
  • Rituximab is also known as Mabthera
  • 1 2 3 4 5 6 7 8 9

    News

    Protected rituximab aims at brain metastases
    Nature - Wednesday, September 11, 2019
    The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
    Doi - Friday, September 6, 2019
    Rituximab or Cyclosporine for Treating Membranous Nephropathy
    Medpagetoday - Wednesday, July 17, 2019
    Rituximab Tops Cyclosporine in Membranous Nephropathy
    Medpage Today - Friday, July 12, 2019
    Rituximab: Suitable for SLE Flare Prevention?
    Medpagetoday - Wednesday, June 12, 2019
    Flare Prevention in Lupus: Consider Rituximab
    Medpage Today - Sunday, May 26, 2019
    Rituximab in SSc Improves Skin, But Not Lungs
    Medpagetoday - Saturday, April 27, 2019
    No Benefit Seen With Rituximab for Chronic Fatigue Syndrome
    Physicians Briefing - Sunday, April 14, 2019
    Rituximab for Systemic Sclerosis: Helps Skin, but Not Lungs
    Medpage Today - Sunday, April 14, 2019
    Rituximab Fails in Chronic Fatigue
    Medpage Today - Thursday, April 4, 2019
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis
    Neurology - Tuesday, February 12, 2019
    Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab
    Nature - Saturday, February 2, 2019
    Effectiveness of tocilizumab, rituximab over other biologics demonstrated
    Medwirenews - Thursday, January 31, 2019
    Tocilizumab, rituximab outperform other biologicals for RA
    Medwirenews - Thursday, January 31, 2019
    Rituximab shows disability benefits in patients with secondary progressive MS
    Medwirenews - Saturday, January 12, 2019
    Rituximab may delay RA onset in at-risk individuals
    Medwirenews - Thursday, December 6, 2018
    Biomarker score reflects rituximab response in RA patients
    Medwirenews - Thursday, December 6, 2018
    Safety and efficacy of rituximab-based first line treatment of chronic GVHD
    Nature - Thursday, December 6, 2018
    MORE NEWS

    Videos

    Rituxan Side Effects With Better Options
         
    Click on the link below for a free video guide to dietary supplements and herbal medicine! http://utahtexans.com/ In this video I want to share with you some of the worst side effects of the drug rituxan and of course give you a few better choices. ...

    What is rituximab?
         

    BCEEEF 2011: Use of comorbidities to determine CLL patient fitness.
         
    Dr Francesc Bosch - Hospital Vall d'Hebron, Barcelona, Spain. Dr Francesc Bosch discusses the importance of looking at comorbidities rather than age when deciding upon treatment for elderly chronic lymphocytic leukaemia (CLL) patients. There is current...

    UPMC Physician Resources: Cancer and Renal Transplantation
         
  • He also came with enlarged lymph node and the lymph node biopsy showed posttransplant lymphoproliferative disease which is a CD 20 positive with EBER positive and serum EBV was positive and the patient was given multiple courses of Rituximab, I would thi...

  • 1 2 3 4 5 6 7 8 9

    Images

    220px Rituxan in action
    crystal structure of rituximab fab in complex with an epitope peptide
    Lymphoma patients now have a number of very effective therapy options, including various forms of chemotherapy, radiotherapy, and targeted drugs such as rituximab.
    220px Rituximab   Mab Tas
    300px Peptide bound to Rituximab FAB
    220px Rituxan in action
    en.wikipedia.org
    crystal structure of rituximab fab in complex with an epitope peptide
    en.wikipedia.org
    Lymphoma patients now have a number of very effective therapy options, including various forms of chemotherapy, radiotherapy, and targeted drugs such as rituximab.
    dana-farber.org
    220px Rituximab Mab Tas
    en.wikipedia.org
    300px Peptide bound to Rituximab FAB
    en.wikipedia.org
    With its reputedly low toxicity profile and narrow targeting of B-cells, Rituxan is an attractive candidate for use as a frontline monotherapy in CLL.
    rituxan 04
    Single Agent Rituxan
    rituxan 03
    Topic: Rituxan Therapy
    With its reputedly low toxicity profile and narrow targeting of B-cells, Rituxan is an attractive candidate for use as a frontline monotherapy in CLL.
    clltopics.org
    rituxan 04
    drugs.com
    Single Agent Rituxan
    clltopics.org
    rituxan 03
    drugs.com
    Topic: Rituxan Therapy
    clltopics.org
    rituxan 02
    rituxan 01
    Immunomodulators & Rituxan
    Rituxan plus Chemotherapy Combinations
    Rituxan, Fludarabine and Cyclophosphamide
    rituxan 02
    drugs.com
    rituxan 01
    drugs.com
    Immunomodulators & Rituxan
    clltopics.org
    Rituxan plus Chemotherapy Combinations
    clltopics.org
    Rituxan, Fludarabine and Cyclophosphamide
    clltopics.org
    CD20 Shaving with Rituxan
    I hope at least a few of you folks are following the complex web of logic that links CD20, Rituxan, Complement, and complement inhibitors CD55 and CD59.
    Rituxan molecule
    Rituxan plus Fenretinide: A Match Made in Heaven?
    Bar chart showing non-Hodgkin lymphoma mortality rates from 1982 to 2008. Beginning in 1982, there were between 6 and 7 deaths per 100,000 people from non-Hodgkin lymphoma. The trend increases each year to peak at just fewer than 9 deaths per 100,000 in 1
    CD20 Shaving with Rituxan
    clltopics.org
    I hope at least a few of you folks are following the complex web of logic that links CD20, Rituxan, Complement, and complement inhibitors CD55 and CD59.
    clltopics.org
    Rituxan molecule
    clltopics.org
    Rituxan plus Fenretinide: A Match Made in Heaven?
    clltopics.org
    Bar chart showing non-Hodgkin lymphoma mortality rates from 1982 to 2008. Beginning in 1982, there were between 6 and 7 deaths per 100,000 people from non-Hodgkin lymphoma. The trend increases each year to peak at just fewer than 9 deaths per 100,000 in 1
    cancer.gov
    Illustration showing how a monoclonal antibody such as rituximab binds to the CD20 molecule on the surface of a malignant B cell.
    Complement Levels in Rituxan Therapy
    Rituxan plus Short Duration Campath
    th Rituximab
    This was because, unlike most RA drugs at the time, rituximab was a B-cell therapy, not a T-cell therapy.
    Illustration showing how a monoclonal antibody such as rituximab binds to the CD20 molecule on the surface of a malignant B cell.
    cancer.gov
    Complement Levels in Rituxan Therapy
    clltopics.org
    Rituxan plus Short Duration Campath
    clltopics.org
    th Rituximab
    niaid.nih.gov
    This was because, unlike most RA drugs at the time, rituximab was a B-cell therapy, not a T-cell therapy.
    arthritisresearchuk.org
    Rituximab antibody that targets B cells
    FRIDAY March 13, 2009 -- The cancer drug Rituxan may offer the first new treatment approved for lupus in 50 years, suggests a small study by U.K. researchers at Imperial College London.
    In Relapsed NHL, Time to Progression Doubles when Gazyva is Added to Rituxan
    The use of novel B-cell receptor (BCR) pathway inhibitors and targeted monoclonal antibodies like rituximab are expanding treatment options for all patients, even those with more compromised immune systems.
    As Drug Maker Quickly Positions Replacement For Rituxan, Questions Of Business Ethics Arise
    Rituximab antibody that targets B cells
    niaid.nih.gov
    FRIDAY March 13, 2009 -- The cancer drug Rituxan may offer the first new treatment approved for lupus in 50 years, suggests a small study by U.K. researchers at Imperial College London.
    drugs.com
    In Relapsed NHL, Time to Progression Doubles when Gazyva is Added to Rituxan
    curetoday.com
    The use of novel B-cell receptor (BCR) pathway inhibitors and targeted monoclonal antibodies like rituximab are expanding treatment options for all patients, even those with more compromised immune systems.
    innovation.org
    As Drug Maker Quickly Positions Replacement For Rituxan, Questions Of Business Ethics Arise
    lymphomainfo.net
    This trial will determine if rituximab is a safe and effective drug for people with myasthenia gravis.
    Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Actemra (tocilizumab) and Xeljanz (tofacitinib) are non-TNF biologics and target other immune system molecules; they may be used if a TNF blocker plus methotrexate is not adequate in rheumatoid
    Rituximab panel 02.png
    Rituximab panel 01.png
    Rituximab label 02.jpg
    This trial will determine if rituximab is a safe and effective drug for people with myasthenia gravis.
    ninds.nih.gov
    Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Actemra (tocilizumab) and Xeljanz (tofacitinib) are non-TNF biologics and target other immune system molecules; they may be used if a TNF blocker plus methotrexate is not adequate in rheumatoid
    drugs.com
    Rituximab panel 02.png
    wikidoc.org
    Rituximab panel 01.png
    wikidoc.org
    Rituximab label 02.jpg
    wikidoc.org
    Rituximab label 01.jpg
    Rituximab clinical studies 10
    Rituximab clinical studies 09
    Rituximab clinical studies 08
    Rituximab clinical studies 07
    Rituximab label 01.jpg
    wikidoc.org
    Rituximab clinical studies 10
    wikidoc.org
    Rituximab clinical studies 09
    wikidoc.org
    Rituximab clinical studies 08
    wikidoc.org
    Rituximab clinical studies 07
    wikidoc.org

    MORE IMAGES